Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1

• Published in: Cardiovascular research Vol. 93; no. 4; pp. 682 - 693
• Main Authors: Bauer, Philip M., Bauer, Eileen M., Rogers, Natasha M., Yao, Mingyi, Feijoo-Cuaresma, Monica, Pilewski, Joseph M., Champion, Hunter C., Zuckerbraun, Brian S., Calzada, Maria J., Isenberg, Jeffrey S.
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 15.03.2012
• Subjects: Animals; Biological and medical sciences; Cardiology. Vascular system; Case-Control Studies; Caveolin 1 - metabolism; CD47 Antigen - metabolism; Cells, Cultured; Disease Models, Animal; Endothelium, Vascular - metabolism; Endothelium, Vascular - pathology; Humans; Hypertension, Pulmonary - chemically induced; Hypertension, Pulmonary - metabolism; Hypertension, Pulmonary - pathology; Hypoxia - metabolism; Hypoxia - pathology; Lung - metabolism; Lung - pathology; Male; Medical sciences; Mice; Mice, Inbred C57BL; Mice, Knockout; Monocrotaline - adverse effects; Nitric Oxide Synthase Type III - metabolism; Original; Oxidative Stress - physiology; Pneumology; Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species - metabolism; Signal Transduction - physiology; Thrombospondin 1 - deficiency; Thrombospondin 1 - genetics; Thrombospondin 1 - metabolism; Up-Regulation - physiology; Caveolin-1; Oxygen; Reactive oxygen species; eNOS; Targeting; Respiratory disease; Cardiovascular disease; Phlebology; Artery; Pulmonary hypertension; Free radical; Pulmonary arterial hypertension; Circulatory system; CD47; Cardiology
• ISSN: 0008-6363; 1755-3245; 1755-3245
• DOI: 10.1093/cvr/cvr356

Pulmonary arterial hypertension (PAH) is a progressive lung disease characterized by pulmonary vasoconstriction and vascular remodelling, leading to increased pulmonary vascular resistance and right heart failure. Loss of nitric oxide (NO) signalling and increased endothelial nitric oxide synthase (eNOS)-derived oxidative stress are central to the pathogenesis of PAH, yet the mechanisms involved remain incompletely determined. In this study, we investigated the role activated CD47 plays in promoting PAH. We report high-level expression of thrombospondin-1 (TSP1) and CD47 in the lungs of human subjects with PAH and increased expression of TSP1 and activated CD47 in experimental models of PAH, a finding matched in hypoxic human and murine pulmonary endothelial cells. In pulmonary endothelial cells CD47 constitutively associates with caveolin-1 (Cav-1). Conversely, in hypoxic animals and cell cultures activation of CD47 by TSP1 disrupts this constitutive interaction, promoting eNOS-dependent superoxide production, oxidative stress, and PAH. Hypoxic TSP1 null mice developed less right ventricular pressure and hypertrophy and markedly less arteriole muscularization compared with wild-type animals. Further, therapeutic blockade of CD47 activation in hypoxic pulmonary artery endothelial cells upregulated Cav-1, increased Cav-1CD47 co-association, decreased eNOS-derived superoxide, and protected animals from developing PAH. Activated CD47 is upregulated in experimental and human PAH and promotes disease by limiting Cav-1 inhibition of dysregulated eNOS.